REMIssion of Type 2 Diabetes Between Intermittently Scanned Continuous Glucose Monitoring and Capillary Blood Glucose Monitoring When Added to Low-calorie Meal Replacement and Diabetes Self-management Education

Launched by LMC DIABETES & ENDOCRINOLOGY LTD. ·

Keywords

ClinConnect Summary

This study, called REMIT2D isCGM, is testing whether using an intermittently scanned continuous glucose monitor (isCGM) helps adults with type 2 diabetes achieve remission (blood sugar levels moving into the prediabetes or normal range) when they start a program that includes a very low-calorie meal plan plus diabetes self-management education. In this randomized, open-label trial, participants are assigned to either isCGM plus the meal plan and education, or to capillary blood glucose monitoring (finger-prick tests) plus the same meal plan and education. The study has three phases over about 18 months, and the main question is whether isCGM leads to more people reaching remission by about 18–30 weeks.

Who can join and what to expect: adults aged 18–75 with type 2 diabetes, BMI 27–44.9, using up to 3 non-insulin diabetes medicines, and with HbA1c levels in ranges allowed by their current treatment, are eligible if they’re not currently using a real-time CGM or isCGM and are willing to follow the meal plan and monitoring. The trial is taking place at several centers across Canada (in Ontario and nearby areas). If you participate, you’ll be randomly assigned to one monitoring method and receive the same low-calorie meal plan and diabetes education. Researchers will track outcomes such as HbA1c, weight, treatment satisfaction, diabetes distress, and CGM metrics, with the primary result expected after the end of Phase 2 (about 18–30 weeks). Results are not yet available.

Gender

ALL

Eligibility criteria